Immune checkpoints blockade inhibitors, such as anti-CTLA-4 and anti-PD-1, are now proven effective cancer treatments. In melanoma, the patients who experience clinical benefits usually have T cell-inflamed tumor microenvironment. Understanding the molecular mechanism explaining lack of T cell infiltration in a major subset of patients should lead to development of new therapeutic strategies that improve spontaneous T cell infiltration into tumors and render these patients responsive to immunotherapies. It has been proposed that the T cell-inflamed (hot) and non-T cell inflamed (cold) phenotypes might be due to the differential expression of immunogenic antigens. To test this hypothesis, we compared the levels of three types of antigens: cancer-testis (CT) antigens, differentiation antigens, and somatic mutational antigens, in hot and cold tumors.
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Using the TCGA data set for malignant melanoma, the patients were segregated according to the presence or absence of the T cell-inflamed gene expression signature in the tumor microenvironment. Transcriptional profiling revealed no differences in the levels of cancer-testis (CT) antigens or differentiation antigens between the hot and the cold tumors. Using exome sequencing of tumor versus germline, a range of 18 to 3001 of non-synonymous mutations was observed in both cohorts. Using the syfpeithi algorithm for HLA-A*0201 patients, a median of 123 mutations having a high immunogenicity score were found in the T cell-inflamed cohort versus 176 in the non-T cell-inflamed. To confirm actual immunogenicity, 321 peptides from hot tumors and 409 peptides from cold tumors have been synthesized. Using a high-throughput T2 binding assay, peptides from both cohorts were found to bind to HLA-A*0201. In vitro priming of T cells using autologous dendritic cells also revealed that peptides from both cohorts could prime human antigen-specific CD8+ T cells. Our results indicate that there is not a lack ofimmunogenic antigens in non-T cell-inflamed melanomas. Other mechanisms must explain T cell exclusion in those cases, such as the recently described Wnt/b-catenin pathway activation. New strategies to promote T cell entry into non-inflamed tumors have a chance for success if immunogenic antigens are indeed present and can be accessed by host immune cells.
